GlassScriptPhysician profile
Ann M Rehm
NPI 1699756536
$2,831.09
in general payments reported to CMS, 2019-2025
29 companies · $743 in 2025
The $743 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $194 · 2021: $139 · 2022: $406 · 2023: $505 · 2024: $488 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.50 |
| Education | $258.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $774.83 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $294.73 | 2019-2023 | |
| Hologic Sales and Service, LLC | $257.88 | 2022-2025 | Acessa Provu System, Myosure Tissue Removal Device, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Daiichi Sankyo INC. | $234.22 | 2019-2025 | Injectafer |
| Sumitomo Pharma America, INC. | $154.44 | 2023-2025 | Myfembree |
| Aspira Women'S Health INC | $126.61 | 2022-2023 | Ova1 |
| Therapeuticsmd, INC. | $118.35 | 2019-2022 | |
| Sage Therapeutics, LLC | $98.84 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $98.05 | 2021-2022 | |
| Exeltis, USA INC. | $97.84 | 2019-2023 | Slynd |
| Organon LLC | $87.18 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $83.51 | 2022-2024 | |
| Pfizer INC. | $58.43 | 2023-2024 | |
| Millicent US INC | $43.56 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Coopersurgical, INC. | $37.40 | 2020-2024 | Endosee |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $32.94 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $22.73 | 2025 | Qelbree |
| Myriad Women'S Health, INC. | $22.71 | 2023 | Myrisk |
| Mimedx Group, INC. | $22.60 | 2025 | |
| Exact Sciences Corporation | $19.67 | 2025 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $19.34 | 2019 | |
| Gynesonics, INC. | $18.96 | 2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Channel Medsystems, INC. | $18.18 | 2025 | |
| Dysis Medical, INC. | $16.40 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.16 | 2019 | |
| Scynexis, INC. | $15.80 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.68 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.99 | 2020 | |
| Duchesnay USA Incorporated | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Rehm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.